Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Eli Lilly and Company ...
Eli Lilly has shared positive two-year results from an open-label extension (OLE) study of Omvoh (mirikizumab-mrkz) in active ...
Eli Lilly has announced results from the VIVID-2 open-label extension study, showing that most patients with moderately to ...
Eli Lilly presents positive results from VIVID-2 open-label extension study of Omvoh to treat Crohn's disease at Crohn's and Colitis Congress: Indianapolis Monday, February 10, 20 ...
With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...
INDIANAPOLIS—Lilly Endowment Inc., a major shareholder in Eli Lilly & Co. (NYSE:LLY), has recently sold a significant portion ...
CNW/ - Pharmascience Canada is proud to announce the launch of Pr pms-RUPATADINE (rupatadine), a treatment that helps relieve nasal and non-nasal ...
Hosted on MSN1d
LLY Rises More Than 4% in a Week: How to Play the StockEli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...
Alvotech and Teva's product is the first biosimilar to the ... UPDATED: Thursday, Jan. 16 at 10:25 a.m. ET Eli Lilly's Omvoh has picked up its second major FDA nod. After the IL-23 inhibitor's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback